For active immunisation of Atlantic salmon to reduce mortality caused by infections with IPNV (infectious pancreatic necrosis), Aeromonas salmonicida subsp. salmonicida (furunculosis), Vibrio salmonicida (cold-water vibriosis), Listonella (Vibrio) anguillarum serotype O1 and O2a (vibriosis), and Moritella viscosa (winter ulcer disease).

Onset of immunity:

500 degree days after vaccination for the bacterial antigens and 608 degree days after vaccination for IPNV.

Duration of immunity:

A. salmonicida and M. viscosa: 18 months.

L. anguillarum O1, L. anguillarum O2a and V. salmonicida: 16 months.

Infectious pancreatic necrosis virus: 4 months.

Dose to be administered and administration route

Intraperitoneal use.

Shake the bottle well before use.

Dosage: a single dose of 0.1 ml.

Administration: intraperitoneally along the central line, approximately 1 pelvic fin length in front of the pelvic fin base in Atlantic salmon.

Vaccination is recommended for fish above 30 grams.

Food should be withheld at least 2 days prior to vaccination.

The fish should be anaesthetised before vaccination.

The length and the diameter of the applied needle should be adapted to the actual fish size. Ensure that the recommended dose is deposited into the abdominal cavity before the needle is withdrawn.

Adverse reactions

Oil adjuvant increases the risk of side effects after vaccination in the form of adhesions and pigmentation in the abdominal cavity.

Moderate adhesions and pigmentation in the abdominal cavity are very commonly observed.

Vaccine residues occur very commonly.

Adhesions with a Speilberg score of 1 to 3 are commonly seen with most of the scores ≤ 2. More extensive changes (Speilberg score 4) uncommonly occur.

A reduction in appetite after vaccination is very commonly observed. The loss of appetite is most pronounced during the first week after vaccination and feed intake is restored within 10 - 12 days. Appetite loss after vaccination does not affect weight at harvest.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)